Browse News
Filter News
Found 33 articles
-
XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform
3/28/2024
XtalPi Inc., a leading global technology company in integrating artificial intelligence and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer.
-
XtalPi and HKU's Advanced Biomedical Instrumentation Centre Sign MoU to Accelerate Deep Tech Commercialization
11/27/2023
XtalPi Inc. and the Advanced Biomedical Instrumentation Centre at the University of Hong Kong have entered a memorandum of understanding that outlines a roadmap for scientific collaboration and commercialization of deep tech developed by ABIC researchers located both in Hong Kong and globally.
-
XtalPi Inc. Unveils "XtalPi Intelligent Automation" and Announces New Automation Facility in Shanghai
8/28/2023
XtalPi Inc., a leading technology platform company renowned for melding physics-based computation, artificial intelligence, and robotics to advance the discovery and evolution of groundbreaking medicines and innovative materials, unveiled its newest brand, XtalPi Intelligent Automation, at the inaugural Intelligent Automation Forum on August 25th, 2023, in Shanghai, China.
-
XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics
5/30/2023
Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company.
-
Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
4/14/2023
Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development.
-
XtalPi Names New COO for U.S. Operations, Bringing Its Autonomous Labs to Boston in Continued Global Expansion
1/11/2023
XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations.
-
XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer
12/19/2022
XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, today announced a strategic collaboration with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), to discover novel treatment candidates for non-small cell lung cancer (NSCLC).
-
XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development, opening a new paradigm for scientific innovation
11/25/2022
XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group.
-
XtalPi Announces Research Collaboration with Janssen
10/27/2022
XtalPi, Inc., a privately-held solution provider accelerating biopharmaceutical research via its integrated technology platform, announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") to deliver chemical matter with validated binding affinities and desirable property profiles.
-
Artificial Intelligence (AI) in Drug Discovery Market To Set Remarkable CAGR Growth of 41.0% By 2029 | Analysed By key Players, Future Trends, Industry Growth And Applications Overview
6/29/2022
A New Research on the Artificial Intelligence (AI) in Drug Discovery Market was conducted across a variety of industries in various regions to produce more than 350+ page reports.
-
META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development
6/13/2022
META Pharmaceuticals, China's first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling 15 million USD.
-
Kintor Pharma Announces 2021 Business Progress and Annual Results
3/25/2022
Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended December 31, 2021.
-
AI in the Pharmaceutical Market Size to Worth Around USD 9.24 Bn by 2030
3/14/2022
The global AI in pharmaceutical market size is expected to be worth around USD 9.24 billion by 2030 from valued at USD 905.91 million in 2021 with a CAGR of 29.4% from 2021 to 2030.
-
Antengene and XtalPi Announce AI-Driven R&D Collaboration
12/16/2021
Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.
-
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
-
XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target
10/27/2021
Signet Therapeutics and XtalPi Inc., announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet.
-
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
-
It takes money to develop new, innovative treatments and this morning, multiple companies have announced significant fundraises. A summary of each financing round is below.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing
3/23/2021
XtalPi, an artificial intelligence drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to 'Drugging the Undruggable®' disease targets.